SuperworthCelularity price to sales ratio CELU
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 1.7×
- 4-year median
- 4.4×
- Against its 4-year history
- 16th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.7× to 17.4×
- Peer median
- 0.4×
Celularity's price to sales ratio is 1.7× as of Oct 23, 2026.
That is below its 4-year median of 4.4×, lower than on 84% of days in the last 4 years.
Over that time it ranged from 0.7× in Jul 2026 to 17.4× in Aug 2022.
The median for 4 large drugmakers of a similar size is 0.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.7× | 0.7× | 2.7× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | 4.1× | 2.8× | 8.1× |
| 2023 | 3.1× | 2.3× | 9.2× |
| 2022 | 10.0× | 8.9× | 17.4× |
Against its peers
Companies in Drug Manufacturers - General nearest Celularity's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| CELUCelularity | 1.7× |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 0.4× |
Where Celularity ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Celularity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.